We are a global specialty and branded pharmaceutical company, improving the health of patients across the world through our high quality and affordable products. Active at every stage of the value chain, we are uniquely diversified by geography, product and manufacturing capability, positioning us well to maximise the value we create for our business and our diverse stakeholders.
We supply medicines to more than 150 countries and have 71 established business offices in more than 50 countries. We focus on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets.
OUR INVESTMENT CASE
Leveraging our strengths and capabilities to deliver long-term shareholder value, while living the Aspen values.
Please click on a title below left for more information.
Responsible corporate citizen and a trusted partner
- We are committed to effective and robust corporate governance making us a trusted partner. We remain committed to continuously improving our reporting, transparency and disclosure.
- We are a signatory to the United Nations Global Compact ("UN Global Compact") Initiative.
- Aspen is a constituent of the FTSE/JSE Responsible Investment Top 30 Index and the global FTSE4Good Index.
Group revenue contribution
by segment (R'million)
Commercial Pharmaceuticals contribution:
Emerging and developed markets (R'million)
SHARE PRICE CENTRE
View share price information for Aspen Holdings.
APN ISIN: ZAE 000066692
JSE data delayed by 15 minutes, page refreshes every 5 minutes. Indicated trade times are actual.
All capital distributions to date
Analysis of shareholders at 30 June 2019
All corporate information and contact details
December 2020 Virtual Annual General Meeting.
December 2020 2020 Virtual Investor Day
March 2021 2021 Interim Results on SENS
March 2021 J.P. Morgan South Africa Healthcare Forum - 2021 Interim Results presentation
September 2021 2021 Year End Results on SENS
September 2021 2021 Year End Results presentation